Global Non-small Cell Lung Cancer Drugs Market 2012-2016

Global Non-small Cell Lung Cancer Drugs Market 2012-2016

Category : Healthcare

TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

TechNavio's analysts forecast the Global Non-small Cell Lung Cancer market to grow at a CAGR of 2.77 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing prevalence of cancer. The Global Ophthalmic Drugs market has also been witnessing the trend of emergence of personalized medicines. However, the increasing use of complementary and alternative medicine could pose a challenge to the growth of this market. 

TechNavio's report, the Global Non-small Cell Lung Cancer Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Non-small Cell Lung Cancer market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space are AstraZeneca plc., Eli Lilly & Co., F. Hoffmann-La Roche Ltd., and Sanofi S.A.

The other vendors mentioned in the report are Bristol-Myers Squibb Co., GlaxoSmithKline Plc., Novartis AG, and OSI Pharmaceuticals Inc.
Key questions answered in this report:
What will the market size be in 2016 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

01. Executive Summary

02. Introduction

03. Market Coverage


Market Overview

Key Offerings

04. Market Landscape

Market Size and Forecast

04.1 Five Forces Analysis

05. Geographical Segmentation

06. Rate of Incidence and Prevalence

07. Vendor Landscape

08. Buying Criteria

09. Market Growth Drivers

10. Drivers and their Impact

11. Market Challenges

12. Impact of Drivers and Challenges

13. Market Trends

14. Key Vendor Analysis


14.1 F. Hoffmann-La Roche Ltd.

Business Overview

Key Information

SWOT Analysis

14.2 AstraZeneca plc

Business Overview

Key Information

SWOT Analysis

14.3 Eli Lilly & Co.

Business Overview

Key Information

SWOT Analysis

14.4 Sanofi S.A.

Business Overview

Key Information

SWOT Analysis

15. Other Reports in this Series



List of Exhibits:

Exhibit 1: Global Non-small Cell Lung Cancer Drugs Market 2012-2016 (US$ billion)

Exhibit 2: Global Non-small Cell Lung Cancer Drugs Market by Geographical Segmentation 2012

Exhibit 3: Global Non-small Cell Lung Cancer Drugs Market by Vendor Segmentation 2012


Enquiry Before Buy
image
Can´t read the image ? refresh here.